

BCAT1 Antibody (Center) Blocking peptide Synthetic peptide Catalog # BP10147c

### **Specification**

# **BCAT1** Antibody (Center) Blocking peptide - Product Information

Primary Accession Other Accession

<u>P54687</u> <u>NP\_001171563.1, NP\_001171562.1,</u> <u>NP\_005495.2, NP\_001171564.1,</u> <u>NP\_001171565.1</u>

#### **BCAT1** Antibody (Center) Blocking peptide - Additional Information

Gene ID 586

Other Names Branched-chain-amino-acid aminotransferase, cytosolic, BCAT(c), Protein ECA39, BCAT1, BCT1, ECA39

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# BCAT1 Antibody (Center) Blocking peptide - Protein Information

Name BCAT1

Synonyms BCT1, ECA39

**Function** 

Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine.

Cellular Location Cytoplasm.

**Tissue Location** 

During embryogenesis, expressed in the brain and kidney. Overexpressed in MYC-induced tumors such as Burkitt's lymphoma



# **BCAT1 Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

#### • **Blocking Peptides**

### BCAT1 Antibody (Center) Blocking peptide - Images

### BCAT1 Antibody (Center) Blocking peptide - Background

This gene encodes the cytosolic form of the enzymebranched-chain amino acid transaminase. This enzyme catalyzes thereversible transamination of branched-chain alpha-keto acids tobranched-chain L-amino acids essential for cell growth. Twodifferent clinical disorders have been attributed to a defect ofbranched-chain amino acid transamination: hypervalinemia andhyperleucine-isoleucinemia. As there is also a gene encoding amitochondrial form of this enzyme, mutations in either gene maycontribute to these disorders. Alternatively spliced transcriptvariants have been described.

#### **BCAT1 Antibody (Center) Blocking peptide - References**

Eijgelsheim, M., et al. Hum. Mol. Genet. 19(19):3885-3894(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Barber, M.J., et al. PLoS ONE 5 (3), E9763 (2010) :Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)